Ashland to Sell Elastomers Business to Lion Copolymer

Ashland said it has reached a "definitive agreement" to sell its Port Neches, Texas-based elastomers business to Lion Copolymer for an undisclosed sum.

The deal is expected to close by the end of the year.

Ashland acquired the elastomers activities, which primarily supply the North American replacement tire market, with its takeover of International Specialty Products in August 2011. The business accounted for around 17% of the Ashland Performance Materials segment's $1.6 billion in sales for fiscal 2014 (Jun. 30).

The decision to sell fits the Wilmington, Delaware-based company's "well-established strategy of divesting non-core assets and reinvesting in higher-margin, specialty chemical businesses where we see attractive growth opportunities," said CEO James J. O'Brien. "We are pleased with the value we received for the business and believe this transaction represents a good strategic fit for Lion," O'Brien added.

Jesse Zeringue, executive vice-president of Lion Copolymer Holdings, said the size of the facility in Port Neches, its access to feedstock and excellent storage capacity, combined with specialty products such as hot styrene-butadiene rubber polymers and high styrene polymers, provide his company with "an excellent growth opportunity."

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.